The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study protocol for a randomised controlled trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Kingslake, Jonathan ^a   Dias, Rebecca ^a   Dawson, Gerard R ^a   Simon, Judit ^b,c   Goodwin, Guy M ^c,d   Harmer, Catherine J ^c   Morriss, Richard ^e   Brown, Susan ^e   Guo, Boliang ^e   Dourish, Colin T ^a   Ruhé, Henricus G ^f   Lever, Anne G ^g   Veltman, Dick J ^g   van Schaik, Anneke ^g   Deckert, Jürgen ^h   Reif, Andreas ⁱ   Stäblein, Michael ⁱ   Menke, Andreas ^h   Gorwood, Philip ^j   Voegeli, Géraldine ^j   Pérez, Victor ^k   Browning, Michael ^a,c,d   more..

^a P1VITAL   (United Kingdom)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Antidepressant; Depression; Prediction; Primary care; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; FEMALE; FRANCE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; SOFTWARE; SPAIN; TREATMENT PLANNING; TREATMENT RESPONSE; UNITED KINGDOM; ADOLESCENT; AFFECT; CLINICAL DECISION MAKING; CLINICAL TRIAL; COGNITION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG EFFECT; ECONOMICS; EUROPE; HEALTH CARE COST; METHODOLOGY; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE; PRIMARY HEALTH CARE; PSYCHOLOGY; QUESTIONNAIRE; RISK FACTOR; TIME FACTOR; TIME TO TREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECT; AGED; ANTIDEPRESSIVE AGENTS; CLINICAL DECISION-MAKING; CLINICAL PROTOCOLS; COGNITION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEPRESSION; EUROPE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; RESEARCH DESIGN; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85035219653     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-2247-2     Document Type: Article

References (26)

1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL, et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010. PLoS Med. 2013;10:e1001547.
2. WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291:2581-90.
3. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3:415-24.
4. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2011;21:655-79.
5. NICE. Treatment and management of depression in adults, including adults with a chronic physical health problem. London: NICE; 2009.
6. Rush MDA. STAR*D: what have we learned? Am J Psychiatry. 2007;164:201-4.
7. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67:1836-55.
8. Harmer CJ, Cowen PJ. 'It's the way that you look at it'-a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci. 2013;368:20120407.
9. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord. 2009;118:87-93.
10. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573-83.
11. Dawson GR, Dourish C, Kingslake J, Harmer C, Goodwin G, Browning M. A precision medicine approach to antidepressant treatment in depression. Eur Neuropsychopharmacol J Eur Coll Neuropsychophamracol. 2015;25:S441.
12. Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry. 2003;160:990-2.
13. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16:199-208.
14. Simon J, Anand P, Gray A, Rugkåsa J, Yeeles K, Burns T. Operationalising the capability approach for outcome measurement in mental health research. Soc Sci Med 1982. 2013;98:187-96.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
16. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-7.
17. Wechsler D. Wechsler Adult Intelligence Scale-3rd ed. San Antonio: Harcourt Assessment; 1997.
18. Gameroff MJ, Wicramaratne P, Weissman MM. Testing the Short and Screener versions of the Social Adjustment Scale - Self-report (SAS-SR). Int J Methods Psychiatr Res. 2012;21:52-65.
19. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-60.
20. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323:1123-4.
21. Goldstein, H. Multilevel statistical models. 4th ed. Hoboken: Wiley; 2011.
22. Kahan BC. Accounting for centre-effects in multicentre trials with a binary outcome-when, why, and how? BMC Med Res Methodol. 2014;14:20.
23. Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ. 2012;345:e5840.
24. Tadić A, Wachtlin D, Berger M, Braus DF, van Calker D, Dahmen N, et al. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression-The EMC trial. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2016;26:705-16.
25. Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Møller K, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry. 2017;17:58.
26. Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter ID, Salvadore G, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharm Basel Switz. 2010;3:19-41.